Communication

News

Polyplus Builds on Research and Commercial mRNA Support Portfolio with in vivo-jetRNA®+ Transfection Reagent

12 September 2022
News

Strasbourg, France, 6 September 2022 – Polyplus, a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, continues to build out the mRNA support portfolio. The team has launched in vivo-jetRNA®+ transfection reagent for in vivo mRNA delivery using a preformed liposome.

The new in vivo-jetRNA®+ transfection reagent an efficient, stable, and safe delivery system leading to 100% mRNA encapsulation for comparable LNP delivery. The ready-to-use format eliminates formulation steps, and the stable liposome size allows for low to high mRNA concentration over time. Applications include prophylactic vaccines, mRNA therapeutics (cancer therapy, rare disease, etc.) and gene editing. A unique feature is the ability to target multiple organs via systemic injection routes in various models with no limitation to liver only.

To know more